Short answer: Per the FDA label, Saxenda starts at 0.6 mg once daily for week 1, then rises weekly: 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3 mg daily from week 5 onward. For adults, 3 mg is the label's recommended dose; the lower doses are for titration only (2.2, Table 1).
Per label section 1, Saxenda is used with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with body weight above 60 kg and obesity, and in adults with overweight plus at least one weight-related condition. This page summarizes the current FDA prescribing information (revised 6/2026). It is not personalized medical advice; your prescriber sets your dose.
The label's dosing schedule (label section 2.2, Table 1):
| Period | Dose | Label note |
|---|---|---|
| Week 1 | 0.6 mg once daily | Starting dose; the label says lower dosages are for titration only in adults |
| Week 2 | 1.2 mg once daily | |
| Week 3 | 1.8 mg once daily | |
| Week 4 | 2.4 mg once daily | |
| Week 5 and onward | 3 mg once daily | Recommended (and maximum) dose |
Maintenance: For adults, the label's recommended dosage is 3 mg once daily; the lower dosages are for titration only, and the label says to discontinue Saxenda if an adult cannot tolerate 3 mg (2.2).
Below is the label schedule laid out week by week, using the earliest timing the label allows. The label lets prescribers stay at a step longer, so a real calendar is often slower. The blank columns are for your own record.
| Week | Label dose | Date | Site / time | Weight | Notes |
|---|---|---|---|---|---|
| Week 1 | 0.6 mg once daily | ||||
| Week 2 | 1.2 mg once daily | ||||
| Week 3 | 1.8 mg once daily | ||||
| Week 4 | 2.4 mg once daily | ||||
| Week 5 | 3 mg once daily | ||||
| Week 6 | 3 mg once daily | ||||
| Week 7 | 3 mg once daily | ||||
| Week 8 | 3 mg once daily | ||||
| Week 9 | 3 mg once daily | ||||
| Week 10 | 3 mg once daily | ||||
| Week 11 | 3 mg once daily | ||||
| Week 12 | 3 mg once daily | ||||
| Week 13 | 3 mg once daily | ||||
| Week 14 | 3 mg once daily | ||||
| Week 15 | 3 mg once daily | ||||
| Week 16 | 3 mg once daily | ||||
| Week 17 | 3 mg once daily | ||||
| Week 18 | 3 mg once daily | ||||
| Week 19 | 3 mg once daily | ||||
| Week 20 | 3 mg once daily |
Printing this page prints the schedule and calendar without the site navigation.
| Product | What it delivers | Pack sizes | Contents |
|---|---|---|---|
| Saxenda prefilled pen (single-patient-use, multi-dose) | Dial-a-dose: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg per injection | Cartons of 3 pens or 5 pens | 18 mg liraglutide in 3 mL (6 mg/mL) |
The label reports these rates from placebo-controlled trials (label section 6.1, Table 2). Percentages are the share of trial participants who reported each reaction.
| Adverse reaction | Placebo (N=1941) | Saxenda (N=3384) |
|---|---|---|
| Nausea | 13.8% | 39.3% |
| Diarrhea | 9.9% | 20.9% |
| Constipation | 8.5% | 19.4% |
| Vomiting | 3.9% | 15.7% |
| Injection site reaction | 10.5% | 13.9% |
| Headache | 12.6% | 13.6% |
| Hypoglycemia in type 2 diabetes (blood glucose <54 mg/dL; Study 2 only) | 6.6% | 12.6% |
| Dyspepsia | 2.7% | 9.6% |
| Fatigue | 4.6% | 7.5% |
| Dizziness | 5% | 6.9% |
| Abdominal pain | 3.1% | 5.4% |
| Increased lipase | 2.2% | 5.3% |
| Upper abdominal pain | 2.7% | 5.1% |
| Gastroenteritis | 3.2% | 4.7% |
| Gastroesophageal reflux disease | 1.7% | 4.7% |
| Abdominal distension | 3% | 4.5% |
| Eructation | 0.2% | 4.5% |
| Urinary tract infection | 3.1% | 4.3% |
| Flatulence | 2.5% | 4% |
| Viral gastroenteritis | 1.6% | 2.8% |
| Insomnia | 1.7% | 2.4% |
| Dry mouth | 1% | 2.3% |
| Asthenia | 0.8% | 2.1% |
| Anxiety | 1.6% | 2% |
When do they happen? The label reports that the percentage of adults reporting nausea declined as treatment continued, and that asthenia, fatigue, malaise, dysgeusia and dizziness were mainly reported within the first 12 weeks, often alongside GI events (6.1). In the adult trials, 9.8% on Saxenda vs 4.3% on placebo stopped treatment because of adverse reactions (6.1).
The label also carries warnings that are not in this table (for example, a boxed warning or pancreatitis and gallbladder warnings where applicable). Read the full label linked under Sources, and report side effects to your prescriber.
Per the label, a missed dose is not made up: the once-daily regimen resumes with the next scheduled dose, with no extra or increased dose. If more than 3 days have passed since the last dose, the label says to restart at 0.6 mg daily and follow the Table 1 escalation again. (label section 2.1) The full walk-through is on the Saxenda missed-dose page.
The label describes a subcutaneous injection once daily at any time of day, without regard to the timing of meals, in the abdomen, thigh, or upper arm. No dosage adjustment is needed if the injection site or timing changes, and sites are rotated within the same region. (label section 2.1)
A simple log makes each titration step easier to talk through with your prescriber. These are the things worth writing down, and how Dose Track handles them:
Your log stays on your phone. See GLP-1 tracking in Dose Track for the full feature list.
Reviewed as of . Section numbers above refer to the FDA prescribing information.
All GLP-1 brand guides · GLP-1 tracking · Supported medications